FDA gingivitis guidance
This article was originally published in The Rose Sheet
Executive Summary
OTC gingivitis products should carry the labeling claim "helps prevent gingivitis" while Rx drugs may include the more scientific phrase "reduction of disease incidence," FDA recommends in a FDL-1draft guidance published in the Federal Register June 28. "Gingivitis: Development & Evaluation of Drugs for Treatment or Prevention" focuses on trial design issues and clinical assessments involved with developing both Rx and OTC products for the condition. Recommended inclusion criteria for clinical trials include "a specified number of teeth present" and "a qualifying baseline plaque index." Guidance also outlines recommended exclusion criteria and defines "prevention" and "treatment"...
You may also be interested in...
CTFA/CHPA request
Consumer Healthcare Products Association and Cosmetic, Toiletry and Fragrance Association seek 60-day extension of comment period on FDA gingivitis drug products draft guidance from Aug. 29 to Oct. 28 to allow time "to coordinate an industry response and to provide the agency with meaningful and substantive comments," associations state in July 15 letter. FDA published a draft guidance June 28 focusing on clinical trial design issues for Rx and OTC gingivitis treatments (1"The Rose Sheet" July 4, 2005, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.